F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA 299(11): 1315-1319

Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
JAMA The Journal of the American Medical Association (Impact Factor: 30.39). 04/2008; 299(11):1315-9. DOI: 10.1001/jama.299.11.1315
Source: PubMed

ABSTRACT Individuals with Li-Fraumeni syndrome (LFS) have an inherited cancer predisposition to a diverse array of malignancies beginning early in life; survivors of one cancer have a markedly elevated risk of additional primary tumors. The underlying genetic defect in the majority of the families is a germline mutation in the TP53 tumor suppressor gene. The diversity of tumors and rarity of families have contributed to the difficulty in devising effective screening recommendations for members of LFS kindreds.
To gather preliminary data with which to evaluate F18-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) imaging as a potential surveillance modality to detect early malignancies in asymptomatic members of LFS kindreds.
Members of LFS families with documented germline TP53 mutations or obligate carrier status, no history of cancer within 5 years of enrollment, and no symptoms of cancer or ill-health were offered FDG-PET/CT scanning as a screening test in a comprehensive US cancer center from 2006 to 2007. Scans were initially reviewed clinically, then centrally reviewed by an expert radiologist.
The primary outcome was the detection of new primary cancers using FDG-PET/CT scanning.
Of 15 individuals, baseline FDG-PET/CT scan identified asymptomatic cancers in 3 (20%). Two individuals had papillary thyroid cancers (stage II and stage III) and one individual had stage II esophageal adenocarcinoma.
These preliminary data provide the first evidence for a potential cancer surveillance strategy that may be worthy of further investigation for patients with LFS. Concerns about radiation exposure and other challenges inherent in screening high-risk patients will require further consideration.

Download full-text


Available from: Lisa M Digianni, Aug 23, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Inzidenz der Weichgewebesarkome liegt bei etwa 3–4 pro 100000 pro Jahr (Zahm u. Fraumeni 1997). Insgesamt sind Weichgewebesarkome für < 1% aller Krebserkrankungen im Erwachsenenalter und etwa 7% der Krebserkrankungen im Kindesalter verantwortlich.
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this system, up to five test articles can be supported concurrently in real time. Data are received via both low- and high-speed telemetry links into a common data acquisition subsystem. The data acquisition subsystem consists of Metraplex and Aydin monitor hardware. Data is then routed into several-purpose telemetry preprocessors where they are tagged, edited and processed. The low-speed telemetry preprocessors are designed to use SEL 3270 computers. The new high-speed telemetry preprocessors use VAX 8600 coupled with Micro VAX II. In the architecture, the analysis and display elements have been combined to form an intelligent workstation environment using commercially available computers and displays. Each workstation can execute several real-time programs and direct data to two 19" high resolution monitors. Function keys, programmable latch keys and other user friendly input devices allow the test engineer to interact with the system and support the test requirements
    European Test Conference, 1989., Proceedings of the 1st; 05/1989
  • [Show abstract] [Hide abstract]
    ABSTRACT: Li-Fraumeni syndrome is a cancer predisposition syndrome associated with soft tissue sarcoma, osteosarcoma, pre-menopausal breast cancer, brain tumors, adrenocortical carcinoma (ACC), and a variety of other neoplasms. Two forms are recognized: classic Li-Fraumeni syndrome (LFS) and Li-Fraumeni-like (LFL) syndrome, which shares some, but not all of the features of LFS. Individuals with LFS are at increased risk of developing multiple primary cancers. Age-specific cancer risks have been calculated. LFS is diagnosed in individuals meeting established clinical criteria. More than 70% of individuals diagnosed clinically have an identifiable disease-causing mutation in TP53, the only gene known to be associated with LFS. Treatment of manifestations: routine management of cancers, except for those with breast cancer, for whom mastectomy is recommended rather than lumpectomy in order to reduce the risks of a second primary tumor and to avoid radiation therapy. Prevention of primary manifestations: Prophylactic mastectomy to reduce the risk of breast cancer is an option for women with a germline TP53 mutation. Prevention of secondary complications: Avoidance of radiation therapy to reduce risk of secondary radiation-induced malignancies. Surveillance: Currently no monitoring regimens have been proven to be beneficial for children or adults with a germline TP53 mutation. It is recommended that: (1) children and adults undergo comprehensive annual physical examination; (2) women undergo age-specific breast cancer monitoring that is routine for women with an increased inherited risk, which includes annual mammograms, breast MRI, and clinical breast examination beginning at age 25 years; and (3) all see a physician promptly for evaluation of lingering symptoms and illnesses. It is suggested that: (1) adults undergo routine screening for colorectal cancer beginning no later than age 25 years; and (2) individuals undergo organ-targeted surveillance based on the pattern of cancer observed in the family. Intensified surveillance imaging for adults and children is being evaluated in investigational settings. Agents/circumstances to avoid: radiation therapy. Evaluation of relatives at risk: It is appropriate to offer genetic counseling and testing to all relatives who are at risk of having a familial TP53 mutation. LFS is inherited in an autosomal dominant manner. The proportion of individuals with a de novo mutation is unknown. Offspring of an affected individual have a 50% chance of inheriting the disease-causing mutation. Predisposition testing for at-risk family members and prenatal testing for pregnancies at increased risk are possible for families in which the disease-causing mutation has been identified.
    GeneReviews™, Edited by Roberta A Pagon, Thomas D Bird, Cynthia R Dolan, Karen Stephens, Margaret P Adam, 01/1999; University of Washington, Seattle.
Show more